Genomicactivation of PPARγ-mediated transcription in bladder cancercan occur via different mechanisms including focal amplification/overexpressionof PPARγ or mutations in PPARγ or RXRα, a NR thatforms a heterodimer with PPARγ and contributes to PPARγ-mediatedcontrol of gene expression.−, , , ,  These findings suggested that targeting PPARγ with pharmacologicalinverse agonists that repress PPARγ-mediated transcription mayhold therapeutic utility in the treatment of bladder cancer, wherePPARγ signaling is hyperactivated. The gene discussed is PPARG; the disease is urinary bladder cancer.